论文部分内容阅读
目的探讨血清胱抑素C和视黄醇结合蛋白用于肿瘤化疗患者肾功能损害监测的临床价值。方法选择2013年3月至2013年12月肿瘤化疗患者120例为观察组,同期体检健康者120例为对照组;比较对照组、观察组化疗前后血清胱抑素C和视黄醇结合蛋白水平,观察组血清肌酐、胱抑素C及视黄醇结合蛋白阳性率等。结果观察组患者化疗后血清胱抑素C和视黄醇结合蛋白水平均显著高于对照组,差异有统计学意义(P<0.05)。观察组患者胱抑素C阳性率[51.67%(62/120)]及视黄醇结合蛋白阳性率[53.33%(64/120)]均高于肌酐阳性率(31.67%),差异有统计学意义(P<0.05)。结论血清胱抑素C和视黄醇结合蛋白用于肿瘤化疗患者肾功能损害监测敏感准确,具有临床应用价值。
Objective To investigate the clinical value of serum cystatin C and retinol binding protein in the monitoring of renal dysfunction in patients with tumor chemotherapy. Methods From March 2013 to December 2013, 120 patients with tumor chemotherapy were selected as the observation group and 120 healthy subjects were selected as the control group. The levels of serum cystatin C and retinol binding protein in the observation group before and after chemotherapy , Observation group serum creatinine, cystatin C and retinol binding protein-positive rate. Results The levels of serum cystatin C and retinol binding protein in the observation group were significantly higher than those in the control group (P <0.05). The positive rate of cystatin C (51.67% (62/120)] and the positive rate of retinol binding protein (53.33% (64/120) in the observation group were higher than that of creatinine (31.67%), the difference was statistically significant Significance (P <0.05). Conclusions Serum cystatin C and retinol binding protein are sensitive and accurate for the monitoring of renal function damage in patients with tumor chemotherapy and have clinical value.